International legal practice Osborne Clarke has advised Turbine, a company simulating cellular decision making to unlock novel oncology therapies, on raising EUR 5.7 million (USD 6.85m) as part of the successful closing of its pre-Series A round. The transatlantic round was co-led by new investors Accel and XTX Ventures and included Boston Millenia Partners who joined the existing syndicate comprising Delin Ventures, Atlantic Labs and o2h Ventures.
Most wet-lab experiments offer limited insight into the complex underlying biology of the disease. As a result, existing preclinical models in oncology often fail to translate into successful drugs in the clinic. To improve these outcomes, Turbine has created the Simulated Cell™ comprising an advanced digital model of human cell behaviour and cloud-based simulated experiments. The Simulated Cell™ can rapidly run unlimited number of experiments in comparison to wet-lab methods.
The platform – guided by AI algorithms – offers significant benefits over industry gold standard screening methods, such as CRISPR, by providing granular insight into the molecular mechanism of target-disease interactions. Supported by an enhanced biological understanding of the target intervention and the subset of cancer patients most likely to respond, Turbine’s simulation-based approach increases the likelihood of clinical success.
The Osborne Clarke team was led by Partner Matthew Edwards who was assisted by Associate Director Jonathan Falconer and Associate Courtney Fowler.
Osborne Clarke’s corporate team is widely recognised as a leading European law firm for companies operating in the life science and healthcare sector team. Its sector team has a strong track record of providing highly sophisticated advice to investors and digital health clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma, medical devices, medtech and digital health companies in the market.